



UNITED STATES PATENT AND TRADEMARK OFFICE

ck
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/721,864

11/24/2000

David Scheinberg

D6126

4077

7590 06/28/2007
Dr. Benjamin Adler
McGREGOR & ADLER, LLP.
8011 Candle Lane
Houston, TX 77071

EXAMINER

DAVIS, MINH TAM B

ART UNIT

PAPER NUMBER

1642

MAIL DATE

DELIVERY MODE

06/28/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/721,864

Applicant(s)

SCHEINBERG ET AL.

Examiner

MINH-TAM DAVIS

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 04 May 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1 and 7 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 7 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 05/04/07 has been entered.

Accordingly, claims 1, 7 are being examined.

Withdrawn Rejection

The 112, first paragraph rejection of claims 1, 7 was withdrawn in view of the amendment.

New Rejections Based on The Amendment

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1642

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1,7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Simonson et al, 1990, Cancer Res, 50 (3 Supp): 9855-9885, of record, in view of Kasperson, FM et al, 1995, Nuclear Med Comm, 16: 468-476, of record, Vieira, MR, et al, 1996, Eur J Surgical Oncology, 22(4): 331-4, of record, and US 6,197,278, of record, and further in view of US 4,444,744A, of record.

Claim 1 is drawn to: A method of increasing the probability of remission after treatment in an individual having a solid cancerous tumor greater than 1 mm in size, comprising the steps of:

(a) selecting an antibody that targets a specific binding site on a tumor cell comprising the solid tumor;

(b) selecting a high specific activity for a bismuth-213/antibody construct from about 10 mCi/mg to about 30 mCi/mg, said construct comprising bismuth-213 conjugated to said antibody via a bifunctional chelant;

(c) selecting a dose of said construct to provide a pharmacologically effective amount of antibody to bind to a sufficient plurality of said targeted sites on tumor cells on an outer layer of tumor cells comprising the solid tumor so that a minimum of two atoms of bismuth-213 delivers at least one alpha particle to each targeted tumor cell comprising said outer layer upon binding the antibody thereto;

(d) intravenously administering the dose of said high specific activity construct to said human, whereupon the tumor cells receiving said alpha particle are killed; and

(e) repeating step (d) wherein each repetition kills an additional layer of tumor cells thereby sequentially reducing the size of the solid tumor, thereby increasing the probability of remission in the individual.

Claim 7 is drawn to: The method of claim 1, wherein said dose is from about 0.1 mg/m² to about 10 mg/m².

Simonson et al teach i.p. administration of **212-Bi labeled antibodies** specific for the mucin antigen TAG-72 into mice previously injected with LS1744T cells. Simonson et al teach that LS1744T cells grow both as solid tumors and ascites in mice, wherein after the development of solid tumor, the mice develop ascites at about 20 days after injection of the tumor cells (p. 985s, second column, last paragraph, and p. 987s, second column, first

Art Unit: 1642

paragraph). Simonson et al teach that the specific activity of the labeled antibody is 5 to **10 uCi/ug** (p.986s, first column, second paragraph), which is the same as 5 to 10 mCi/mg and is within the range of the claimed specific activity. Simonson et al further teach that for advanced tumors of 13 days after injection of tumor cells, with single and repeated administration of Bi-212 labeled antibody, 56% decrease in tumor mass is obtained (p.986s, first column, third paragraph and figure 1 on page 986s). Simonson et al teach that 13 days after injection, the tumor mass is 3 gm on average (figure 1). Simonson et al teach that the efficacy of the treatment would be **even better** if the radiolabeled antibody recognizes an **antigen on cell surface** of target cell, rather than the mucin antigen TAG-72, which is secreted (p.987s, second column).

Simonson et al do not teach a method of killing a tumor greater than 1 mm in size, comprising intravenously administering antibodies that are labeled with Bi-213, at a dose adequate to deliver a minimum of 1 alpha track per cell, or at a dose of about 0.1 mg/m² to about 10 mg/m².

Although Simonson et al do not teach that the treated tumors are at least 1 mm in size, one would have expected that the size of the solid tumors taught by Simonson et al would be at least **1 mm** in size, because the solid tumors taught by Simonson et al have 3gm average in weight, and are advanced tumors after 13 days of growth.

Kaspersen et al teach that **Bi-213** is an alternative to Bi-212, with the advantage of safer and easier production (p.475, first column, first paragraph).

Vieira, MR, et al teaches that imaging of breast cancer tissues could begin 10 minutes after **intravenous** administration of radiolabeled monoclonal antibodies (abstract, p.332, third

Art Unit: 1642

paragraph). In other words, radiolabeled monoclonal antibodies could reach the breast cancer tissues within minutes after its intravenous administration.

US 6,197,278 teaches that after i.v. administration, localization of a radiolabeled targeting protein, annexin, a protein having high affinity for anionic phospholipid surface, in the target tissue can be obtained in only a few minutes (columns 9-10, especially last two paragraphs of column 9, bridging column 10).

US 4,447,444A teaches use of radiolabeled antibodies to cancer **cell surface antigens** for cancer immunotherapy.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to **substitute Bi-212 with Bi-213** in the method of treating cancer taught by Simonson et al, because Bi-213 has the advantage of safer and easier production, as taught by Kasperon et al. It would have been obvious to replace antibodies specific for the mucin antigen TAG-72 taught by Simonson et al, with an antibody that targets a membrane cancer specific antigen on cancer cells, as suggested by Simonson et al, because an antibody to a cancer membrane antigen would be more effective than an antibody to a secreted antigen for targeting a cancer cell, and because antibodies specific for cancer specific antigens on cancer cell surface in cancer immunotherapy have been successfully used in the art, as taught by US 4,447,444A. It would have been obvious to administer the labeled antibody intravenously, because it is a convenient, alternative, routine route of administration of labeled antibodies for immunotherapy. It would have been obvious to administer the labeled antibody once or repeatedly, as taught by Simonson et al, to ensure destruction of cancer cells.

Art Unit: 1642

One would have expected that the Bi-213 radiolabeled antibody would reach the target cancer cells within minutes after its intravenous administration, and that the Bi-213 radiolabeled antibody would have ample time to kill target cancer cells, despite the relative short half life of alpha particle, such as Bi-213, because targeting compounds, including radiolabeled antibody, have been shown to be able to reach the target cells within minutes after their intravenous administration, as taught by Vieira, MR, et al, and US 6,197,278.

With regards to the dosage of the labeled antibodies recited in claims 1, 7, to determine optimum dosage is within the level of ordinary skill in the art. See In re Kronig, 190 USPQ 425.

One of ordinary skill in the art would have been motivated to treat tumors having at least 1mm in size using an antibody labeled with Bi-213, that targets a specific binding site on tumor cells, with a reasonable expectation of success.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, SHANON FOLEY can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH TAM DAVIS
June 15, 2007

/Larry R. Helms/
Supervisory Patent Examiner